Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.58B 16.18B 15.08B 28.44B 1,904B 29.02B 195B 75.42B 935B 75.19B 73.57B 3,253B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.96B 17.45B 16.26B 30.67B 2,053B 31.3B 210B 81.33B 1,008B 81.09B 79.33B 3,508B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+3.30%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
122.99
10 years 11.48
Extreme 11.48
159.54
Date Insider Type Main position Quantity % Market Cap.
03-22Free

Chief Executive Officer

2,533,955 1.3275%
03-22Issuer sale

General Counsel

93,932 0.0492%
03-22Free

Executive/Senior Manager

199,374 0.1044%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+92.14%+11.73% 20.03B
+1.91%+5.44%+119.07%+134.98% 4.69B
+4.29%+15.67%+99.91%+233.38% 3.43B
+5.11%+3.45%-26.18%-38.57% 1.98B
-4.57%-6.59%+128.16%-43.61% 1.86B
+2.63%+7.81%+55.17%+244.12% 1.47B
-1.44%+6.77%+145.02%-50.52% 920M
-3.37%+6.49%-12.37%+39.66% 884M
-3.83%+1.31%+12.59% - 537M
+3.53%-0.02%-36.78%-18.54% 468M
Average +0.52%+5.71%+57.67%+56.96% 3.63B
Weighted average by Cap. +1.20%+3.04%+86.19%+51.79%

Financials

2024 2025
Net sales 2.76B 2.42B 2.23B 2.08B 3.92B 262B 4B 26.82B 10.39B 129B 10.36B 10.13B 448B 3.25B 2.85B 2.62B 2.45B 4.61B 309B 4.71B 31.56B 12.23B 152B 12.19B 11.93B 527B
Net income -1.03B -903M -831M -775M -1.46B -97.82B -1.49B -10B -3.87B -48.01B -3.86B -3.78B -167B -208M -183M -168M -157M -295M -19.77B -301M -2.02B -783M -9.7B -781M -764M -33.77B
Net Debt 1.74B 1.53B 1.4B 1.31B 2.47B 165B 2.52B 16.89B 6.54B 81.09B 6.52B 6.38B 282B 1.57B 1.38B 1.27B 1.18B 2.23B 149B 2.28B 15.26B 5.91B 73.27B 5.9B 5.77B 255B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock